Yatharth Hospital FY26 revenue +36%, FY27 margin 24-25%

What the FY26 update signals

Yatharth Hospital & Trauma Care Services Ltd reported strong growth for the quarter and year ended March 31, 2026, supported by the ramp-up of newer hospitals and a higher-value speciality mix. FY26 annual revenue rose 36% year-on-year to ₹1,207.2 crore. For Q4, revenue increased 47% year-on-year to ₹341.6 crore.

The company also highlighted a net cash position of ₹116.0 crore, which management positioned as a balance sheet support for the next expansion phase. The stated capacity roadmap remains centred on scaling to 5,000 beds over the next few years, led by a cluster-based approach in North India.

FY26 revenue growth and balance sheet position

For FY26, Yatharth attributed the 36% year-on-year revenue growth to two operating levers mentioned in its update: scaling of newer hospitals and a high-value speciality mix. While the company did not provide a full income statement in the provided text, it reiterated an EBITDA margin band for the next phase of expansion and discussed operating assumptions for newly added assets.

A key datapoint in the update was net cash of ₹116.0 crore. In hospital expansion cycles, net cash is often scrutinised because it determines how quickly new facilities can be funded and stabilised without stretching leverage. In Yatharth’s case, the company positioned this balance sheet strength as a base for capacity additions in NCR and other North India markets.

Q4 FY26: acceleration led by new hospitals

In Q4, revenue reached ₹341.6 crore, up 47% year-on-year. The update also quantified the contribution of newer hospitals: Faridabad Sector-20 and New Delhi facilities accounted for 11% of quarterly revenue.

The company also integrated a 250-bedded hospital in Agra effective February 1, 2026. Management described Agra as a feeder hub for specialised treatments such as Oncology and Organ Transplants, strengthening the broader NCR cluster.

Capacity additions and how new assets are scaling

Yatharth’s expansion update included operating indicators for specific facilities. The company described blended occupancy at 67% and reported that its Sector-20 hospital recorded 43% occupancy during the quarter, with 125 beds operational against a capacity of around 400 beds.

For Agra, the company said it began operations in February with around 150 operational beds and plans to expand to 250 beds in the coming quarters. These details matter because they outline how quickly recently added capacity is being commissioned and utilised.

The company also stated that it added 700 beds during the quarter through the opening of new hospitals in Model Town (Delhi) and Faridabad, and through the acquisition of Shantived Hospital in Agra with 250 beds.

Expansion roadmap: Gurugram and the 5,000-bed target

A central piece of the growth plan is the acquisition of an under-construction 250-bedded hospital in Sector 40, Gurugram. The company disclosed an investment outlay of ₹200 crore and guided that the Gurugram hospital is expected to be operational by April 2027.

Alongside Gurugram, management reiterated its stated ambition to scale to 5,000 beds. One portion of the update noted that 3,200 to 3,250 beds were already announced as part of the three-year target. Another portion clarified how timelines are being framed: deals announced over the next three years, with full operationalisation over four to five years.

Guidance: revenue momentum and margin band

On outlook, management said it is confident of sustaining and potentially surpassing FY26 year-on-year growth in FY27, with FY27 revenue growth expected to exceed FY26’s 36% year-on-year growth.

On margins, the company reiterated a blended EBITDA margin guidance of 24% to 25% over the next 2 to 3 years, even as it continues to invest in growth. The update also stated that margin guidance remains at 24% to 25% for FY27, while indicating expectations of improved EBITDA margins.

Separately, management guided for average revenue per occupied bed (ARPOB) to grow 8% to 10% annually, with new facilities expected to lift group averages.

Brokerage view: BUY rating and key risks flagged

The provided text also included an initiation note describing Yatharth as an emerging healthcare player in North India, with a ‘BUY’ rating and a 12-month price target of INR 920. The note cited a projected 30% revenue growth CAGR from FY25 to FY28 and linked this to plans to double bed capacity to around 5,000 by FY30.

The same note flagged risks including a high government patient mix and rising competition. It also mentioned improving corporate governance and operational efficiencies as supportive factors.

Operating metrics from company materials

The update referenced company presentation metrics on scale and utilisation. It cited mature hospitals running at 60% to 91% occupancy with EBITDA margins of 29%+ and stated that new hospitals are designed to operate on 100% cash/TPA payers.

It also included a Q3 FY26 snapshot: revenue of ₹320 crore (+46% YoY), EBITDA of ₹74 crore (+35% YoY), occupancy of 67% (+11% YoY), and ARPOB of ₹33,744 (+10% YoY). These numbers provide context on the growth trajectory and the operating base preceding Q4.

Key numbers at a glance

Market impact: what investors will track next

From a market perspective, the most actionable disclosures are the FY26 and Q4 revenue growth rates, the reiterated EBITDA margin band, and the cadence of bed additions. The net cash position of ₹116.0 crore indicates the company has disclosed liquidity headroom while it pursues a capex-heavy expansion cycle.

Investors are also likely to monitor how quickly newer assets progress from ramp-up to breakeven. Management expects Faridabad to reach breakeven within 12 months and Model Town within 15 months, with a targeted breakeven occupancy of 30% to 35% of full operational capacity for these two hospitals.

Analysis: why the 5,000-bed roadmap matters

Yatharth’s update frames growth through a cluster model anchored around NCR and major North India cities, reinforced by feeder hubs such as Agra for specialised treatments. The disclosed timeline distinction is important: reaching 5,000 beds through announced deals within about three years versus operationalising those beds over four to five years.

The margin guidance of 24% to 25% suggests the company is signalling stability in profitability even as capacity expands. At the same time, the update indicates that mature hospitals operate at EBITDA margins of 29%+ and high occupancy levels, implying that the consolidated margin band is being shaped by the ramp-up phase of newer hospitals.

Conclusion

Yatharth Hospital closed FY26 with 36% year-on-year revenue growth to ₹1,207.2 crore and ended the year with net cash of ₹116.0 crore, while reiterating a 24% to 25% EBITDA margin guidance during its expansion cycle. The near-term operational focus is on integrating recently added assets, scaling occupancies, and executing the Gurugram hospital project targeted to open by April 2027. The next set of milestones for investors will be the pace of bed operationalisation, performance of new hospitals toward stated breakeven timelines, and follow-through on the 5,000-bed roadmap.